Feldman has received research, speaking and/or consulting support from: AbbVie, Accordant, Almirall, Amgen, Arcutis, Arena, Argenx, Biocon, Boehringer Ingelheim, Bristol Myers Squibb, Caremark, Celgene, Dermavant, Eli Lilly, Eurofins, Forte, Galderma, GlaxoSmithKline/Stiefel, Helsinn, Informa, Johnson & Johnson, Leo Pharma, Menlo, Merck, Mylan, Novan, Novartis, Ortho Dermatology, Pfizer, Qurient, Regeneron, Samsung, Sanofi, Sun Pharma, Teladoc, the National Biological Corporation, the National Psoriasis Foundation, UCB, UpToDate, and vTv Therapeutics
[1]International Diabetes Federation, IDF Diabetes Atlas 2024, International Diabetes Federation, diabetesatlas.org Mexico's 2023 documented 38.9 percent of obesity prevalence among adults, while 37.3 percent of the population is classified as overweight or obese, creating a high patient pool of individuals
L.LaurindoL
CJC-1295 (No DAC) acts on the GHRH receptor